The Next Steps for CAR T-Cell Therapy in DLBCL

Amit Patel, BSc, MBBS, PhD, reviews key takeaways from the 2021 European Society for Blood and Marrow Transplantation symposium regarding the use of CAR T-cell therapy for patients with relapsed/refractory diffuse large B-cell lymphoma.

EP. 1: Unmet Needs in Relapsed/Refractory DLBCL

April 27th 2021

An expert in hematology oncology, Amit Patel, BSc, MBBS, PhD, reviews the unmet needs for patients with relapsed/refractory diffuse large B-cell lymphoma.

EP. 2: Options for CAR-T Therapy in the Third-Line Setting

April 27th 2021

A key opinion leader in diffuse large B-cell lymphoma provides a historical perspective on third-line options for CAR T-cell therapy and shares insights on both clinical trial and real-world data.

EP. 3: Best Practices for Early Referral and Bridging Therapy

May 6th 2021

Amit Patel, BSc, MBBS, PhD, discusses best practices for referring patients to CAR T centers earlier and provides advice on bridging therapy to debulk disease burden at the time of CAR T-cell therapy.

EP. 4: Optimizing Patient Selection for CAR T-Cell Therapy

May 6th 2021

A key opinion leader in hematology and oncology shares insights on factors to consider for optimal patient selection and treatment sequencing, such as thresholds for tolerability, renal function, and cardiac ejection fraction.

EP. 5: Research on CAR T Therapy in Earlier Lines of Treatment

May 6th 2021

Amit Patel, BSc, MBBS, PhD, discusses currently ongoing clinical trials of CAR T-cell therapy in first- and second-line treatment settings and comments on potential developments on the horizon.